EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Rebisufligene etisparvovec: The first AAV9-mediated SGSH gene therapy approved for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA)

Chen Pang, Yueyi Sun, Jianjun Gao

Drug Discoveries & Therapeutics · 31.10.2026 · 20 (5) · 403-404

DOI: 10.5582/ddt.2026.01082 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Discoveries & Therapeutics, erschienen am 31.10.2026. Verfasst von Chen Pang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China. Hauptthemen laut MEDLINE: Mucopolysaccharidosis III, Genetic Therapy, Dependovirus, Hydrolases. Die Arbeit nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mucopolysaccharidosis IIIGenetic TherapyDependovirusHydrolasesHumansGene Therapy AgentsHeparan SulfateTreatment OutcomeGenetic Vectors

Stichwörter der Autor:innen

Sanfilippo syndromegene therapyheparan sulfatemucopolysaccharidosisrebisufligene etisparvovec

Substanzen

Heparan SulfateHydrolasesN-sulfoglucosamine sulfohydrolase

Autor:innen und Institutionen

  • Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China.

Zitieren

APA

Pang, C., Sun, Y., & Gao, J. (2026). Rebisufligene etisparvovec: The first AAV9-mediated SGSH gene therapy approved for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA). Drug Discoveries & Therapeutics, 20(5), 403-404. https://doi.org/10.5582/ddt.2026.01082

Vancouver

Pang C, Sun Y, Gao J. Rebisufligene etisparvovec: The first AAV9-mediated SGSH gene therapy approved for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA). Drug Discoveries & Therapeutics. 2026;20(5):403-404. doi:10.5582/ddt.2026.01082

BibTeX
@article{Pang2026,
  author = {Pang, Chen and Sun, Yueyi and Gao, Jianjun},
  title = {Rebisufligene etisparvovec: The first AAV9-mediated SGSH gene therapy approved for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA)},
  journal = {Drug Discoveries & Therapeutics},
  year = {2026},
  volume = {20},
  number = {5},
  pages = {403--404},
  doi = {10.5582/ddt.2026.01082}
}
Kostenlos starten →